SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2018 / Cilt: 48 - Sayı: 1

Stem Cell Treatment in Retinal Diseases: Recent Developments

Ayşe ÖNER
Pages
33–38
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review focuses on new developments in stem cell therapy fordegenerative retinal diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stem cells are undifferentiated cells which have the ability to self-renew and differentiate into mature cells.
📊
Key Findings & Data:They are highly proliferative,implying that an unlimited number of mature cells can be generated from a given stem cell source.
💡
Conclusion & Impact:This review focuses on new developments in stem cell therapy fordegenerative retinal diseases.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Stem cells are undifferentiated cells which have the ability to self-renew and differentiate into mature cells. They are highly proliferative,implying that an unlimited number of mature cells can be generated from a given stem cell source. On this basis, stem cell replacementtherapy has been evaluated in recent years as an alternative for various pathologies. Degenerative retinal diseases cause progressive visualdecline which originates from continuing loss of photoreceptor cells and outer nuclear layers. Theoretically, this therapy will enablethe generation of new retinal cells from stem cells to replace the damaged cells in the diseased retina. In addition, stem cells are able toperform multiple functions, such as immunoregulation, anti-apoptosis of neurons, and neurotrophin secretion. With recent progress inexperimental stem cell applications, phase I/II clinical trials have been approved. These latest stem cell transplantation studies showedthat this therapy is a promising approach to restore visual function in eyes with degenerative retinal diseases such as retinitis pigmentosa,Stargardts’ macular dystrophy, and age-related macular degeneration. This review focuses on new developments in stem cell therapy fordegenerative retinal diseases.

🔖

Cite This Article

ÖNER, A. (2022). Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi, Cilt: 48 - Sayı: 1, 33–38. https://ajindex.com/articles/637771

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Limoli PG, Limoli C, Vingolo EM, Scalinci SZ, Nebbioso M. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016;7:46913-46923.
  2. Satarian L, Nourinia R, Safi S, Kanavi MR, Jarughi N, Daftarian N, Arab L, Aghdami N, Ahmadieh H, Baharvand H. Intravitreal Injection of Bone Marrow Mesenchymal Stem Cells in Patients with Advanced Retinitis Pigmentosa; a Safety Study. J Ophthalmic Vis Res. 2017;12:58-64.
  3. Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, Pandya HK, Leonard RE 2nd, Parrot MB, Rosenfeld PJ, Flynn HW Jr, Goldberg JL. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N Engl J Med. 2017;376:1047-1053.
  4. Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissuederived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther. 2016;7:178. Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014;56:81-89.
  5. Siqueira RC, Messias A, Messias K, Arcieri RS, Ruiz MA, Souza NF, Martins LC, Jorge R. Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial) Stem Cell Res Ther. 2015; 6:29. Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina. 2011;31:1207-1214.
  6. Haddad-Mashadrizeh A, Bahrami AR, Matin MM, Edalatmanesh MA, Zomorodipour A, Gardaneh M, Farshchian M, Momeni-Moghaddam M. Human adipose-derived mesenchymal stem cells can survive and integrate into the adult rat eye following xenotransplantation. Xenotransplantation. 2013;20:165-176.
  7. Castanheira P, Torquetti L, Nehemy MB, Goes AM. Retinal incorporation and differentiation of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq Bras Oftalmol. 2008;71:644-650.
  8. Huang C, Zhang J, Ao M, Li Y, Zhang C, Xu Y, Li X, Wang W. Combination of retinal pigment epithelium cell-conditioned medium and photoreceptor outer segments stimulate mesenchymal stem cell differentiation toward a functional retinal pigment epithelium cell phenotype. J Cell Biochem. 2012;113:590-598. Tsuruma K